Issue

Vol. 18 (2026)

Bi-Polar Bioenergetic Intervention via a Pathology Self-Adaptive Single-Atom Nanocatalyst for Diabetic Tumor Postoperative Management

https://doi.org/10.1007/s40820-026-02169-w
Jiajie Chen
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Jimin Huang
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Zhibo Yang
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Kai Tang
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Chengtie Wu
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Huamao Ye
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China
Jianlin Shi
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China
Yufang Zhu
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China

Corresponding Author: Yufang Zhu

zjf2412@163.com

Nano-Micro Letters, Vol. 18 (2026), Article Number: 346

Abstract

Diabetes aggravates postoperative tumor recurrence and impairs wound healing due to divergent metabolic adaptations to hyperglycemia in tumor versus normal cells. Current therapeutics fail due to the incapabilities in adaptively modulating the metabolic bifurcation across the contradictory pathological contexts. Here, we address this challenge by developing a platinum (Pt) single-atom nanocatalyst (PtSNC) with microenvironments-selective multienzyme-mimicking activities to pioneer a bi-polar bioenergetic intervention strategy. In acidic and reduced nicotinamide adenine dinucleotide (NADH)-overexpressed tumor niches, it exhibits NADH oxidase (NOX)-, oxidase-, and peroxidase-like activities, depleting NADH reserves and generating highly reactive Pt = O species to disrupt energy metabolism and induce both apoptosis/ferroptosis. While it shows NOX-, catalase-, and superoxide dismutase-like activities in neutral diabetic wounds, rectifying hyperglycemia-induced cellular NAD+/NADH abnormity and bioenergetic disorder to revitalize the cells and tissues, with promoting angiogenesis and mitigating local inflammation to accelerate regeneration. Murine diabetic melanoma resection models demonstrate its extensive capacity in effectively eradicating residual tumor tissues and suppressing the recurrence, and promoting diabetic wound healing concurrently without systemic toxicity, making PtSNC a safe and potent nanotherapeutic for diabetic tumor postoperative therapy. This study holds promise for the application of single-atom catalytic medicines in precision therapy for intractable diseases featuring pathological metabolic bifurcation.


Highlights:
1 A high-density and well-structured platinum single-atom nanocatalyst (PtSNC) with pathological contexts-selective multienzyme-mimicking activities is developed to pioneer a bi-polar bioenergetic intervention strategy and break the hyperglycemia-induced metabolic paradox.
2 The PtSNC disrupts energy metabolism and triggers ferroptosis/apoptosis via depleting nicotinamide adenine dinucleotide (NADH) reserves and producing highly reactive Pt = O species in tumor niches, but rectifies cellular NAD+/NADH abnormity and bioenergetic disorder in diabetic wounds, offering a promising solution to diabetic tumor postoperative therapy.

Keywords

Single-atom nanocatalyst Metabolic bifurcation Bioenergetic intervention Catalytic therapy Diabetic tumor postoperative management
Chen, Jiajie, Jimin Huang, Zhibo Yang, Kai Tang, Chengtie Wu, Huamao Ye, Jianlin Shi, and Yufang Zhu. 2026. “Bi-Polar Bioenergetic Intervention via a Pathology Self-Adaptive Single-Atom Nanocatalyst for Diabetic Tumor Postoperative Management”. Nano-Micro Letters 18 (April):346. https://doi.org/10.1007/s40820-026-02169-w.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. NCD Risk Factor Collaboration (NCD-RisC, Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 404(10467), 2077–2093 (2024). https://doi.org/10.1016/S0140-6736(24)02317-1
  2. E.W. Gregg, Y. Li, J. Wang, N.R. Burrows, M.K. Ali et al., Changes in diabetes-related complications in the United States, 1990-2010. N. Engl. J. Med. 370(16), 1514–1523 (2014). https://doi.org/10.1056/NEJMoa1310799
  3. B. Carstensen, S.H. Read, S. Friis, R. Sund, I. Keskimäki et al., Cancer incidence in persons with type 1 diabetes: a five-country study of 9, 000 cancers in type 1 diabetic individuals. Diabetologia 59(5), 980–988 (2016). https://doi.org/10.1007/s00125-016-3884-9
  4. S.K. Garg, H. Maurer, K. Reed, R. Selagamsetty, Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes. Metab. 16(2), 97–110 (2014). https://doi.org/10.1111/dom.12124
  5. D.-S. Kim, P.E. Scherer, Obesity, diabetes, and increased cancer progression. Diabetes Metab. J. 45(6), 799–812 (2021). https://doi.org/10.4093/dmj.2021.0077
  6. D. Mallardo, R. Woodford, A.M. Menzies, L. Zimmer, A. Williamson et al., The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. J. Transl. Med. 21(1), 753 (2023). https://doi.org/10.1186/s12967-023-04607-4
  7. D. Wu, D. Hu, H. Chen, G. Shi, I.S. Fetahu et al., Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 559(7715), 637–641 (2018). https://doi.org/10.1038/s41586-018-0350-5
  8. C.J. Balentine, J. Wilks, C. Robinson, C. Marshall, D. Anaya et al., Obesity increases wound complications in rectal cancer surgery. J. Surg. Res. 163(1), 35–39 (2010). https://doi.org/10.1016/j.jss.2010.03.012
  9. W. Xu, Z. Chen, L. Zhang, Impact of diabetes on the prognosis of patients with oral and oropharyngeal cancer: a meta-analysis. J. Diabetes Investig. 15(8), 1140–1150 (2024). https://doi.org/10.1111/jdi.14223
  10. R. Kanehara, A. Goto, T. Watanabe, K. Inoue, M. Taguri et al., Association between diabetes and adjuvant chemotherapy implementation in patients with stage III colorectal cancer. J. Diabetes Investig. 13(10), 1771–1778 (2022). https://doi.org/10.1111/jdi.13837
  11. H.K.A. El-Shreef, O.Y.M. Taha, H.A. Abd El Hafeez, A.I. Abd El-Rheem Abo Shoka, Role of gastric bypass surgery in control of blood sugar in obese uncontrolled type 2 diabetic patients. Diabetol. Metab. Syndr. 16(1), 47 (2024). https://doi.org/10.1186/s13098-024-01281-4
  12. J. Wu, Z. Jin, H. Zheng, L.-J. Yan, Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications. Diabet Metabol Syndrome Obesity 9, 145–153 (2016). https://doi.org/10.2147/DMSO.S106087
  13. M.J. Charron, S. Bonner-Weir, Implicating PARP and NAD+ depletion in type I diabetes. Nat. Med. 5(3), 269–270 (1999). https://doi.org/10.1038/6479
  14. K. Okabe, K. Yaku, K. Tobe, T. Nakagawa, Implications of altered NAD metabolism in metabolic disorders. J. Biomed. Sci. 26(1), 34 (2019). https://doi.org/10.1186/s12929-019-0527-8
  15. N. Xie, L. Zhang, W. Gao, C. Huang, P.E. Huber et al., NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 5(1), 227 (2020). https://doi.org/10.1038/s41392-020-00311-7
  16. I.A.M. van den Oever, H.G. Raterman, M.T. Nurmohamed, S. Simsek, Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010, 792393 (2010). https://doi.org/10.1155/2010/792393
  17. Y. Li, J. Li, C. Zhao, L. Yang, X. Qi et al., Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice. Metabolism 114, 154402 (2021). https://doi.org/10.1016/j.metabol.2020.154402
  18. Y. Xiong, C. Xiao, Z. Li, X. Yang, Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem. Soc. Rev. 50(10), 6013–6041 (2021). https://doi.org/10.1039/d0cs00718h
  19. W. Li, X. Zhang, H. Sang, Y. Zhou, C. Shang et al., Effects of hyperglycemia on the progression of tumor diseases. J. Exp. Clin. Cancer Res. 38(1), 327 (2019). https://doi.org/10.1186/s13046-019-1309-6
  20. Y. Su, Y. Luo, P. Zhang, H. Lin, W. Pu et al., Glucose-induced CRL4(COP1)-p53 axis amplifies glycometabolism to drive tumorigenesis. Mol. Cell 83(13), 2316-2331.e7 (2023). https://doi.org/10.1016/j.molcel.2023.06.010
  21. M. Bosso, D. Haddad, A. Al Madhoun, F. Al-Mulla, Targeting the metabolic paradigms in cancer and diabetes. Biomedicines 12(1), 211 (2024). https://doi.org/10.3390/biomedicines12010211
  22. L. Zhou, M.-L. Zhan, Y. Tang, M. Xiao, M. Li et al., Effects of β-caryophyllene on arginine ADP-ribosyltransferase 1-mediated regulation of glycolysis in colorectal cancer under high-glucose conditions. Int. J. Oncol. 53(4), 1613–1624 (2018). https://doi.org/10.3892/ijo.2018.4506
  23. Q. Hao, Z. Huang, Q. Li, D. Liu, P. Wang et al., A novel metabolic reprogramming strategy for the treatment of diabetes-associated breast cancer. Adv. Sci. 9(6), 2102303 (2022). https://doi.org/10.1002/advs.202102303
  24. C. Lennicke, H.M. Cochemé, Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol. Cell 81(18), 3691–3707 (2021). https://doi.org/10.1016/j.molcel.2021.08.018
  25. R. Zhang, B. Jiang, K. Fan, L. Gao, X. Yan, Designing nanozymes for in vivo applications. Nat. Rev. Bioeng. 2(10), 849–868 (2024). https://doi.org/10.1038/s44222-024-00205-1
  26. Y. Wang, X. Jia, S. An, W. Yin, J. Huang et al., Nanozyme-based regulation of cellular metabolism and their applications. Adv. Mater. 36(10), 2301810 (2024). https://doi.org/10.1002/adma.202301810
  27. W. Peng, W. Tai, B. Li, H. Wang, T. Wang et al., Inhalable nanocatalytic therapeutics for viral pneumonia. Nat. Mater. 24(4), 637–648 (2025). https://doi.org/10.1038/s41563-024-02041-5
  28. J. Chen, Y. Zhu, C. Wu, J. Shi, Nanoplatform-based cascade engineering for cancer therapy. Chem. Soc. Rev. 49(24), 9057–9094 (2020). https://doi.org/10.1039/d0cs00607f
  29. H. Xiang, W. Feng, Y. Chen, Single-atom catalysts in catalytic biomedicine. Adv. Mater. 32(8), 1905994 (2020). https://doi.org/10.1002/adma.201905994
  30. X. Lu, L. Kuai, F. Huang, J. Jiang, J. Song et al., Single-atom catalysts-based catalytic ROS clearance for efficient psoriasis treatment and relapse prevention via restoring ESR1. Nat. Commun. 14, 6767 (2023). https://doi.org/10.1038/s41467-023-42477-y
  31. F. Cao, L. Zhang, Y. You, L. Zheng, J. Ren et al., An enzyme-mimicking single-atom catalyst as an efficient multiple reactive oxygen and nitrogen species scavenger for sepsis management. Angew. Chem. Int. Ed. 59(13), 5108–5115 (2020). https://doi.org/10.1002/anie.201912182
  32. Y. Liu, B. Wang, J. Zhu, X. Xu, B. Zhou et al., Single-atom nanozyme with asymmetric electron distribution for tumor catalytic therapy by disrupting tumor redox and energy metabolism homeostasis. Adv. Mater. 35(9), 2208512 (2023). https://doi.org/10.1002/adma.202208512
  33. T. Ye, C. Chen, D. Wang, C. Huang, Z. Yan et al., Protective effects of Pt-N-C single-atom nanozymes against myocardial ischemia-reperfusion injury. Nat. Commun. 15(1), 1682 (2024). https://doi.org/10.1038/s41467-024-45927-3
  34. Q. Xu, Y. Zhang, Z. Yang, G. Jiang, M. Lv et al., Tumor microenvironment-activated single-atom platinum nanozyme with H2O2 self-supplement and O2-evolving for tumor-specific cascade catalysis chemodynamic and chemoradiotherapy. Theranostics 12(11), 5155–5171 (2022). https://doi.org/10.7150/thno.73039
  35. N. Hay, Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat. Rev. Cancer 16(10), 635–649 (2016). https://doi.org/10.1038/nrc.2016.77
  36. A. Chiarugi, C. Dölle, R. Felici, M. Ziegler, The NAD metabolome: a key determinant of cancer cell biology. Nat. Rev. Cancer 12(11), 741–752 (2012). https://doi.org/10.1038/nrc3340
  37. J. Park, Q. Jiang, D. Feng, L. Mao, H.-C. Zhou, Size-controlled synthesis of porphyrinic metal–organic framework and functionalization for targeted photodynamic therapy. J. Am. Chem. Soc. 138(10), 3518–3525 (2016). https://doi.org/10.1021/jacs.6b00007
  38. J. Chen, S. Lin, D. Zhao, L. Guan, Y. Hu et al., Palladium nanocrystals-engineered metal–organic frameworks for enhanced tumor inhibition by synergistic hydrogen/photodynamic therapy. Adv. Funct. Mater. 31(4), 2006853 (2021). https://doi.org/10.1002/adfm.202006853
  39. L. Jiao, G. Wan, R. Zhang, H. Zhou, S.-H. Yu et al., From metal–organic frameworks to single-atom Fe implanted N-doped porous carbons: efficient oxygen reduction in both alkaline and acidic media. Angew. Chem. Int. Ed. 57(28), 8525–8529 (2018). https://doi.org/10.1002/anie.201803262
  40. J. Qin, H. Liu, P. Zou, R. Zhang, C. Wang et al., Altering ligand fields in single-atom sites through second-shell anion modulation boosts the oxygen reduction reaction. J. Am. Chem. Soc. 144(5), 2197–2207 (2022). https://doi.org/10.1021/jacs.1c11331
  41. M. Huo, L. Wang, Y. Wang, Y. Chen, J. Shi, Nanocatalytic tumor therapy by single-atom catalysts. ACS Nano 13(2), 2643–2653 (2019). https://doi.org/10.1021/acsnano.9b00457
  42. Z. Li, Y. Chen, S. Ji, Y. Tang, W. Chen et al., Iridium single-atom catalyst on nitrogen-doped carbon for formic acid oxidation synthesized using a general host-guest strategy. Nat. Chem. 12(8), 764–772 (2020). https://doi.org/10.1038/s41557-020-0473-9
  43. A.J. Covarrubias, R. Perrone, A. Grozio, E. Verdin, NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 22(2), 119–141 (2021). https://doi.org/10.1038/s41580-020-00313-x
  44. D.V. Titov, V. Cracan, R.P. Goodman, J. Peng, Z. Grabarek et al., Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science 352(6282), 231–235 (2016). https://doi.org/10.1126/science.aad4017
  45. X. Liu, J. Li, A. Zitolo, M. Gao, J. Jiang et al., Doped graphene to mimic the bacterial NADH oxidase for one-step NAD+ supplementation in mammals. J. Am. Chem. Soc. 145(5), 3108–3120 (2023). https://doi.org/10.1021/jacs.2c12336
  46. M. Rahmati, M.-S. Safdari, T.H. Fletcher, M.D. Argyle, C.H. Bartholomew, Chemical and thermal sintering of supported metals with emphasis on cobalt catalysts during Fischer–Tropsch synthesis. Chem. Rev. 120(10), 4455–4533 (2020). https://doi.org/10.1021/acs.chemrev.9b00417
  47. J. Chen, X. Zheng, J. Zhang, Q. Ma, Z. Zhao et al., Bubble-templated synthesis of nanocatalyst Co/C as NADH oxidase mimic. Natl. Sci. Rev. 9(3), nwab186 (2021). https://doi.org/10.1093/nsr/nwab186
  48. C.D. Putnam, A.S. Arvai, Y. Bourne, J.A. Tainer, Active and inhibited human catalase structures: ligand and NADPH binding and catalytic mechanism. J. Mol. Biol. 296(1), 295–309 (2000). https://doi.org/10.1006/jmbi.1999.3458.
  49. G.E.O. Borgstahl, H.E. Parge, M.J. Hickey, W.F. Beyer, R.A. Hallewell et al., The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell 71(1), 107–118 (1992). https://doi.org/10.1016/0092-8674(92)90270-M
  50. L. Huang, J. Chen, L. Gan, J. Wang, S. Dong, Single-atom nanozymes. Sci. Adv. 5(5), eaav5490 (2019). https://doi.org/10.1126/sciadv.aav5490
  51. H. Huang, W. Geng, X. Wu, Y. Zhang, L. Xie et al., Spiky artificial peroxidases with V−O−Fe pair sites for combating antibiotic-resistant pathogens. Angew. Chem. 136(1), e202310811 (2024). https://doi.org/10.1002/ange.202310811
  52. L. Jiao, J. Wu, H. Zhong, Y. Zhang, W. Xu et al., Densely isolated FeN4 sites for peroxidase mimicking. ACS Catal. 10(11), 6422–6429 (2020). https://doi.org/10.1021/acscatal.0c01647
  53. X. Huang, J.T. Groves, Oxygen activation and radical transformations in heme proteins and metalloporphyrins. Chem. Rev. 118(5), 2491–2553 (2018). https://doi.org/10.1021/acs.chemrev.7b00373
  54. E. Katsyuba, M. Romani, D. Hofer, J. Auwerx, NAD+ homeostasis in health and disease. Nat. Metab. 2(1), 9–31 (2020). https://doi.org/10.1038/s42255-019-0161-5
  55. A.G. Rodríguez, J.Z. Rodríguez, A. Barreto, S. Sanabria-Barrera, J. Iglesias et al., Impact of acute high glucose on mitochondrial function in a model of endothelial cells: role of PDGF-C. Int. J. Mol. Sci. 24(5), 4394 (2023). https://doi.org/10.3390/ijms24054394
  56. G. Al-Kafaji, M.A. Sabry, C. Skrypnyk, Time-course effect of high-glucose-induced reactive oxygen species on mitochondrial biogenesis and function in human renal mesangial cells. Cell Biol. Int. 40(1), 36–48 (2016). https://doi.org/10.1002/cbin.10520
  57. Z. Li, B. Yang, Z. Yang, X. Xie, Z. Guo et al., Supramolecular hydrogel with ultra-rapid cell-mediated network adaptation for enhancing cellular metabolic energetics and tissue regeneration. Adv. Mater. 36(15), 2307176 (2024). https://doi.org/10.1002/adma.202307176
  58. R. Palty, W.F. Silverman, M. Hershfinkel, T. Caporale, S.L. Sensi et al., NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc. Natl. Acad. Sci. U. S. A. 107(1), 436–441 (2010). https://doi.org/10.1073/pnas.0908099107
  59. Y.J. Liu, J. Sulc, J. Auwerx, Mitochondrial genetics, signalling and stress responses. Nat. Cell Biol. 27(3), 393–407 (2025). https://doi.org/10.1038/s41556-025-01625-w
  60. I. Vercellino, L.A. Sazanov, The assembly, regulation and function of the mitochondrial respiratory chain. Nat. Rev. Mol. Cell Biol. 23(2), 141–161 (2022). https://doi.org/10.1038/s41580-021-00415-0
  61. C.S. Helker, J. Eberlein, K. Wilhelm, T. Sugino, J. Malchow et al., Apelin signaling drives vascular endothelial cells toward a pro-angiogenic state. Elife 9, e55589 (2020). https://doi.org/10.7554/eLife.55589
  62. W.-J. Pannekoek, A. Post, J.L. Bos, Rap1 signaling in endothelial barrier control. Cell Adhes. Migr. 8(2), 100–107 (2014). https://doi.org/10.4161/cam.27352
  63. O. Warburg, F. Wind, E. Negelein, The metabolism of tumors in the body. J. Gen. Physiol. 8(6), 519–530 (1927). https://doi.org/10.1085/jgp.8.6.519
  64. J. Chen, Y. Zhu, C. Wu, J. Shi, Engineering lactate-modulating nanomedicines for cancer therapy. Chem. Soc. Rev. 52(3), 973–1000 (2023). https://doi.org/10.1039/d2cs00479h
  65. R.J. DeBerardinis, J.J. Lum, G. Hatzivassiliou, C.B. Thompson, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7(1), 11–20 (2008). https://doi.org/10.1016/j.cmet.2007.10.002
  66. C.N. Birts, A. Banerjee, M. Darley, C.R. Dunlop, S. Nelson et al., p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators. Sci. Signal. 13(630), eaau9529 (2020). https://doi.org/10.1126/scisignal.aau9529
  67. Y. He, M.M. Sun, G.G. Zhang, J. Yang, K.S. Chen et al., Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 425 (2021). https://doi.org/10.1038/s41392-021-00828-5
  68. F. Fontana, G. Giannitti, S. Marchesi, P. Limonta, The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int. J. Biol. Sci. 20(8), 3113–3125 (2024). https://doi.org/10.7150/ijbs.89942
  69. J. Chen, Y. Wang, J. Huang, Z. Yang, H. Niu et al., Cascade specific endogenous Fe3+ interference and in situ catalysis for tumor therapy with stemness suppression. Natl. Sci. Rev. 12(2), nwae434 (2024). https://doi.org/10.1093/nsr/nwae434
  70. X. Ma, J. Yan, G. Zhou, Y. Li, M. Ran et al., Fabrication of metal nuclear acid framework to enable carrier-free MNAzyme self-delivery for gastric cancer treatment. Adv. Funct. Mater. 34(45), 2406650 (2024). https://doi.org/10.1002/adfm.202406650
  71. X. Chen, P.B. Comish, D. Tang, R. Kang, Characteristics and biomarkers of ferroptosis. Front. Cell Dev. Biol. 9, 637162 (2021). https://doi.org/10.3389/fcell.2021.637162
  72. N.B. Hentzen, R. Mogaki, S. Otake, K. Okuro, T. Aida, Intracellular photoactivation of caspase-3 by molecular glues for spatiotemporal apoptosis induction. J. Am. Chem. Soc. 142(18), 8080–8084 (2020). https://doi.org/10.1021/jacs.0c01823
  73. R.J. DeBerardinis, N.S. Chandel, Fundamentals of cancer metabolism. Sci. Adv. 2(5), e1600200 (2016). https://doi.org/10.1126/sciadv.1600200
  74. W.S. Yang, R. SriRamaratnam, M.E. Welsch, K. Shimada, R. Skouta et al., Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2), 317–331 (2014). https://doi.org/10.1016/j.cell.2013.12.010
  75. C. Gorrini, I.S. Harris, T.W. Mak, Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12(12), 931–947 (2013). https://doi.org/10.1038/nrd4002
  76. L. Galluzzi, O. Kepp, M.G. Vander Heiden, G. Kroemer, Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 12(11), 829–846 (2013). https://doi.org/10.1038/nrd4145
  77. A. Sato, M. Okada, K. Shibuya, E. Watanabe, S. Seino et al., Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res. 12(1), 119–131 (2014). https://doi.org/10.1016/j.scr.2013.09.012
  78. L. Deng, C. Du, P. Song, T. Chen, S. Rui et al., The role of oxidative stress and antioxidants in diabetic wound healing. Oxid. Med. Cell. Longev. 2021(1), 8852759 (2021). https://doi.org/10.1155/2021/8852759
  79. A. Joorabloo, T. Liu, Recent advances in reactive oxygen species scavenging nanomaterials for wound healing. Exploration 4(3), 20230066 (2024). https://doi.org/10.1002/EXP.20230066
  80. H. Chen, Y. Cheng, J. Tian, P. Yang, X. Zhang et al., Dissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes. Sci. Adv. 6(20), eaba4311 (2020). https://doi.org/10.1126/sciadv.aba4311
  81. X. Zhang, G. Li, G. Chen, D. Wu, X. Zhou et al., Single-atom nanozymes: a rising star for biosensing and biomedicine. Coord. Chem. Rev. 418, 213376 (2020). https://doi.org/10.1016/j.ccr.2020.213376
  82. Y. Fan, S. Liu, Y. Yi, H. Rong, J. Zhang, Catalytic nanomaterials toward atomic levels for biomedical applications: from metal clusters to single-atom catalysts. ACS Nano 15(2), 2005–2037 (2021). https://doi.org/10.1021/acsnano.0c06962
  83. L. Yang, S. Dong, S. Gai, D. Yang, H. Ding et al., Deep insight of design, mechanism, and cancer theranostic strategy of nanozymes. Nano-Micro Lett. 16(1), 28 (2023). https://doi.org/10.1007/s40820-023-01224-0
  84. S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen et al., Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv. Sci. 6(3), 1801733 (2018). https://doi.org/10.1002/advs.201801733
  85. S. Zhao, J. Hou, L. Deng, Z. Qi, N. Tao et al., Lactate-modulating nanozyme-mediated mitochondrial respiration block for tumor immunosuppression remodeling. Angew. Chem. Int. Ed. 64(17), e202422203 (2025). https://doi.org/10.1002/anie.202422203
  86. W. Yang, X. Yang, L. Zhu, H. Chu, X. Li et al., Nanozymes: activity origin, catalytic mechanism, and biological application. Coord. Chem. Rev. 448, 214170 (2021). https://doi.org/10.1016/j.ccr.2021.214170
  87. X. Hu, B. Zhang, M. Zhang, W. Liang, B. Hong et al., An artificial metabzyme for tumour-cell-specific metabolic therapy. Nat. Nanotechnol. 19(11), 1712–1722 (2024). https://doi.org/10.1038/s41565-024-01733-y
Read More
Author biographies are not available.
Download this PDF file
PDF SUPPLEMENTARY FILE

Most read articles by the same author(s)